Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 in refractory/relapsed acute myeloid leukemia patients.
SVB Leerink analyst Marc Goodman upgrades Satsuma Pharmaceuticals (NASDAQ:STSA) from Market Perform to Outperform and raises the price target from $5 to $15.